The rising popularity of GLP-1 'microdoses' for cosmetic weight loss is outpacing scientific understanding, according to a weight-loss doctor writing in STAT News. These subclinical doses are being used without the evidence base that supports standard prescribing.
The physician argues that patients are self-administering or obtaining off-protocol prescriptions for small amounts of these drugs. The expert warns that the long-term safety and efficacy of such minimal dosing remain entirely unknown, particularly for individuals who are not obese or diabetic.
There are no clinical trials or peer-reviewed data supporting microdosing for cosmetic purposes, the doctor notes. This practice exists in a regulatory grey area, as GLP-1 drugs are approved only for specific indications at established dose ranges.
If safety issues emerge, the physician cautions, they could undermine trust in these medications for the patients who actually need them. The trend also risks normalizing pharmaceutical use for purely aesthetic reasons without medical oversight.
"Long term, we don't know what tiny doses of GLP-1s for cosmetic weight loss can do," the doctor writes, emphasizing the absence of data on this approach.